Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.
2.

Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study.

Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1284-90. doi: 10.1016/j.pnpbp.2011.03.021.

PMID:
21515329
3.

Dysregulated relationship of inflammation and oxidative stress in major depression.

Rawdin BJ, Mellon SH, Dhabhar FS, Epel ES, Puterman E, Su Y, Burke HM, Reus VI, Rosser R, Hamilton SP, Nelson JC, Wolkowitz OM.

Brain Behav Immun. 2013 Jul;31:143-52. doi: 10.1016/j.bbi.2012.11.011.

4.

Effects of antidepressant treatment on total antioxidant capacity and free radical levels in patients with major depressive disorder.

Chang CC, Lee CT, Lan TH, Ju PC, Hsieh YH, Lai TJ.

Psychiatry Res. 2015 Dec 15;230(2):575-80. doi: 10.1016/j.psychres.2015.10.006.

PMID:
26476591
5.

Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems.

Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S.

Hum Psychopharmacol. 2007 Mar;22(2):67-73.

PMID:
17299810
7.

Peripheral biomarkers in animal models of major depressive disorder.

Carboni L.

Dis Markers. 2013;35(1):33-41. doi: 10.1155/2013/284543. Review.

8.

Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in Major Depressive Disorder: a voxel-based morphometry study.

Jung J, Kang J, Won E, Nam K, Lee MS, Tae WS, Ham BJ.

J Affect Disord. 2014 Dec;169:179-87. doi: 10.1016/j.jad.2014.08.018.

PMID:
25200096
9.

The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis.

Hannestad J, DellaGioia N, Bloch M.

Neuropsychopharmacology. 2011 Nov;36(12):2452-9. doi: 10.1038/npp.2011.132.

10.

Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis.

Jiménez-Fernández S, Gurpegui M, Díaz-Atienza F, Pérez-Costillas L, Gerstenberg M, Correll CU.

J Clin Psychiatry. 2015 Dec;76(12):1658-67. doi: 10.4088/JCP.14r09179.

PMID:
26579881
11.

Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.

Drewniany E, Han J, Hancock C, Jones RL, Lim J, Nemat Gorgani N, Sperry JK 3rd, Yu HJ, Raffa RB.

J Clin Pharm Ther. 2015 Apr;40(2):125-30. doi: 10.1111/jcpt.12238.

PMID:
25545040
12.

Abnormal temporal difference reward-learning signals in major depression.

Kumar P, Waiter G, Ahearn T, Milders M, Reid I, Steele JD.

Brain. 2008 Aug;131(Pt 8):2084-93. doi: 10.1093/brain/awn136.

PMID:
18579575
14.
15.

Oxidative stress, inflammation and treatment response in major depression.

Lindqvist D, Dhabhar FS, James SJ, Hough CM, Jain FA, Bersani FS, Reus VI, Verhoeven JE, Epel ES, Mahan L, Rosser R, Wolkowitz OM, Mellon SH.

Psychoneuroendocrinology. 2017 Feb;76:197-205. doi: 10.1016/j.psyneuen.2016.11.031.

PMID:
27960139
16.

Oxidative stress in major depressive and anxiety disorders, and the association with antidepressant use; results from a large adult cohort.

Black CN, Bot M, Scheffer PG, Penninx BW.

Psychol Med. 2017 Apr;47(5):936-948. doi: 10.1017/S0033291716002828.

PMID:
27928978
17.
18.
19.

Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (S) levels in medicated patients with major depressive disorder compared with controls.

Kurita H, Maeshima H, Kida S, Matsuzaka H, Shimano T, Nakano Y, Baba H, Suzuki T, Arai H.

J Affect Disord. 2013 Apr 5;146(2):205-12. doi: 10.1016/j.jad.2012.09.004.

PMID:
23102506
20.

Emerging drugs for major depressive disorder.

Connolly KR, Thase ME.

Expert Opin Emerg Drugs. 2012 Mar;17(1):105-26. doi: 10.1517/14728214.2012.660146. Review.

PMID:
22339643

Supplemental Content

Support Center